Viral safety of C1-inhibitor NF

Terpstra, Fokke G.; Kleijn, Miranda; Koenderman, Anky H. L.; Over, J; Engelenburg, F.A.C. van; Schuitemaker, Hanneke; Wout, Angélique B. van ′t

doi:10.1016/j.biologicals.2006.08.005

Cited by 44 publications

(27 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…pdhC1INH. Although some side effects have been described, 1,32,33,[73][74][75][76] there is no known specific side effect that affects only female patients.…”

Section: Special Features Of Hae-c1-inh Treatment In Female Patientsmentioning

confidence: 99%

International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency

Caballero

Farkas

Bouillet

et al. 2012

Journal of Allergy and Clinical Immunology

211

367

View full text Add to dashboard Cite

“…pdhC1INH. Although some side effects have been described, 1,32,33,[73][74][75][76] there is no known specific side effect that affects only female patients.…”

Section: Special Features Of Hae-c1-inh Treatment In Female Patientsmentioning

confidence: 99%

International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency

Caballero

Farkas

Bouillet

et al. 2012

Journal of Allergy and Clinical Immunology

211

367

View full text Add to dashboard Cite

“…In 1985, the safety of C1-INH concentrate improved after the introduction of a step in which the concentrate was heated for 10 hours at 60 °C to inactivate viruses (Cicardi et al 1995). Also, one company now uses a nanofi ltration step in which a 15 nm fi lter is used to remove viruses and even prions (Terpstra et al 2007). None of the studies using either Lev's or CSL Behring's products have found any evidence of viral seroconversion with C1-INH concentrate infusions; however, earlier studies before viral inactivation procedures demonstrated HCV transmission secondary to C1-INH from Immuno produced C1-INH (Cicardi et al 1995).…”

Section: Discussionmentioning

confidence: 99%

Treatment of hereditary angioedema with plasma-derived C1 inhibitor

Prematta

Craig³

2008

TCRM

View full text Add to dashboard Cite

“…It is presented in 500 U vials of a lyophilized product for intravenous administration, which has to be stored at 2-25 C [8], and when reconstituted, a 50 IU/mL solution is formed. It has an excellent safety post-launch record after more than 35 years of its availability [54][55][56].…”

Section: Us Consensus For the Management Of Children With C1-inh-haementioning

confidence: 99%

Short‐Term Prophylaxis in Odontostomatological, Maxillofacial and ENT Procedures in Patients with Hereditary Angioedema Due to C1‐Inhibitor Deficiency

Palomo¹,

Caballero²

2017

A Comprehensive Review of Urticaria and Angioedema

View full text Add to dashboard Cite

Oestrogens, trauma, infections or stress has been described as triggers for angioedema (AE) attacks in patients with hereditary angioedema due to C1-inhibitor deficiency (C1-INH-HAE). Microtrauma can precipitate the onset of acute AE attacks, and thus, dental-oral procedures carry a high risk of triggering them and also an increased risk of death from asphyxiation due to the AE location. In the past, without proper specific treatment, the overall mortality after dental surgery in patients with C1-INH-HAE was up to 30-40%. Some dental-oral, medical and/or surgical procedures are susceptible to receive "short-term prophylaxis" (STP) in order to reduce the risk of AE. We describe the published case reports of dental-oral, maxillofacial and ear, nose and throat (ENT) procedures in patients with C1-INH-HAE. Different consensus algorithms and clinical guidelines have been published for managing dental-oral, maxillofacial and otolaryngological procedures (DOMFOPs) and will be reviewed below. Based on the clinical experience of the Department of Allergology of the University Hospital La Paz (Madrid) and the University General Hospital Nuestra Señora del Prado (Talavera de la Reina), these algorithms have been updated and modified. We advise to classify procedures according to the risk of producing AE as minor, intermediate and major risks.

show abstract

Viral safety of C1-inhibitor NF

Cited by 44 publications

References 18 publications

International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency

International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency

Treatment of hereditary angioedema with plasma-derived C1 inhibitor

Short‐Term Prophylaxis in Odontostomatological, Maxillofacial and ENT Procedures in Patients with Hereditary Angioedema Due to C1‐Inhibitor Deficiency

Contact Info

Product

Resources

About